Compare Biogen Inc (BIIB) vs Lemonade Inc (LMND) Price & Performance

Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.

The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.

Lemonade (LMND) trades at $70.62, up 0.16% on the day, with a bullish technical signal from moving averages and ADX indicators. Revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, while net losses are narrowing, with the net margin improving from -116.02% to -22.43% over the same period. Recent news highlights expansion into new states and a renegotiated reinsurance program, improving cost structure and capital efficiency.

The outlook is mixed; strong revenue growth and narrowing losses present a long-term opportunity, but the stock trades above the consensus price target of $67.00, with 40% of analysts rating it a sell. Key risks include persistent unprofitability, high valuation multiples, and execution challenges in scaling the AI-driven insurance model. Positive cash flow from operations is projected for 2026, a potential inflection point.